Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 

International Congress of Parkinson’s Disease and Movement Disorders ®

Congress
Main Content

Parallel Session 2401

Translational Genetics in Parkinson’s Disease: Focus on GBA1 and LRRK2

Monday, October 6, 2025
14:00 - 15:30 | Room TBD

In this session, the faculty will present the biology, biomarkers, potential therapeutic agents and trial design for LRRK2 and GBA1-related Parkinson's disease. The path to effective treatments incorporating common genetic variation will be discussed.


Chairs:

Huw Morris, United Kingdom
Tatyana Simuni, USA

Presenters:

Developing an Effective Therapy for LRRK2-Related PD
Esther Sammler, United Kingdom

Developing an Effective Therapy for GBA1-Related PD
Alessio Di Fonzo, Italy

Identifying New Therapeutic Targets from GWAS
Huifang Shang, China, Peoples Republic

CSPC Liaisons:

Huw Morris, United Kingdom

Learning Objectives

At the conclusion of this session, participants should be better able to:

  1. Describe genetic variation and biology of LRRK2, as well as trial design for LRRK2 related therapies
  2. Describe genetic variation and biology of GBA1, as well as trial design for GBA1 related therapies
  3. Discuss how to incorporate common genetic variation (single nucleotide variants / polymorphisms - SNVs) into clinical trials for targeted therapies

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Intermediate / Experienced

Focus

Translational